Lintuzumab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL |
Chemical Data
C H N O Molecular Weight | ||
Lintuzumab is a humanized monoclonal antibody designed for the treatment of cancer. It targets the CD33 antigen, a protein commonly found on the surface of leukemia cells, particularly in acute myeloid leukemia (AML). Lintuzumab is intended to bind to these cells, marking them for destruction by the body's immune system.
Mechanism of Action[edit | edit source]
Lintuzumab works by targeting the CD33 antigen present on leukemia cells. The binding of lintuzumab to CD33 triggers the immune system to attack the marked cells. This process is known as antibody-dependent cellular cytotoxicity (ADCC), which is a common mechanism of action for therapeutic antibodies in oncology.
Clinical Trials[edit | edit source]
Clinical trials have been conducted to evaluate the efficacy and safety of lintuzumab in treating patients with AML. The results have shown variable outcomes, and as of the last update, lintuzumab has not received approval from regulatory bodies such as the Food and Drug Administration (FDA) for public use.
Development and Regulatory Status[edit | edit source]
Originally developed by a biopharmaceutical company, lintuzumab has undergone several phases of clinical trials. Despite showing some promise in early trials, later studies have not consistently demonstrated a significant benefit in terms of survival rates among treated patients compared to standard therapies. Consequently, the development of lintuzumab has faced challenges, including the discontinuation of some trials due to lack of clear efficacy.
Future Prospects[edit | edit source]
Research continues in the hope of improving the efficacy of lintuzumab, possibly by combining it with other therapeutic agents or by targeting different patient subsets where the expression of CD33 is higher and more uniform.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
